Clinical Trials
22 trialsNCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00005029 2018-04-12
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00287859 2017-11-29
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT00004221 2017-08-09
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
GOG Foundation
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00313612 2015-11-27
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003382 2013-06-10
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
GOG Foundation
Phase 1 Terminated
NCT01177501 2012-11-19
ITOV04
Assistance Publique - HĂ´pitaux de Paris
Phase 1 Terminated
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00322920 2008-02-15
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
University of Alabama at Birmingham
Phase 1 Terminated
NCT00194935 2006-09-13
Weekly Topotecan Therapy in Patients With Ovarian Cancer
Weill Medical College of Cornell University
Phase 2 Terminated